We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Fusion Antibodies Plc | FAB | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.40 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.40 | 3.40 | 3.40 | 3.40 | 3.40 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 23/7/2024 15:00 by thiopia 04/07/2024 Fusion Antibodies PLC Trading update18/07/2024 Fusion Antibodies PLC Launch of New Interactive Investor Hub 22/07/2024 Fusion Antibodies PLC Director/PDMR Shareholding Think they might be trying to tell us something? Something about business being #FAB maybe ? |
Posted at 18/7/2024 08:37 by ksddw2 There is a reason why they have created this interactive investor hub. Things are about to get very interesting |
Posted at 16/7/2024 15:31 by troutisout Some working hard on the BBs to keep it down. Investors getting in now will be well rewarded.The mkt cap is tiny and will increase as more news is released, some may trade it others will wait for the multi bags on the horizon |
Posted at 04/6/2024 15:30 by gtc1508 hxxps://youtu.be/39NInvestor presentation |
Posted at 28/5/2024 12:29 by soultrading Mayfair investor presentation tomorrow evening, |
Posted at 20/5/2024 10:57 by gtc1508 Fusion’s market capitalisation is £3.3m, suggesting an EV of £2.1m, based on year £1.2m end cash. We consider this to represent an interesting special situation geared to the success of Fusion’s recovery plan, where almost no value is currently being ascribed to its class leading antibody discovery technologies. This unusual situation has arisen as a result of the steep decline in revenue Fusion experienced in H2 FY23 that extended into FY24.Given there is evidence of a turnaround in its fortunes and helped by an improved funding environment for biotech generally and its order book is now on an upward trajectory, our investment thesis is that investors will start to recognise the value inherent in Fusion’s class leading antibody discovery technology. To highlight this, we would draw attention to the valuation of Absci (Nasdaq: ABSI), an albeit much-larger US/Canadian-based firm that has an AI-led approach to antibody drug design. This company has a market capitalisation of $535m and cash of $72m, so has an EV of $463m. |
Posted at 16/5/2024 18:12 by gtc1508 Investor presentation link |
Posted at 15/5/2024 16:36 by bobaxe1 Investor meet company presentation tomorrow 11am |
Posted at 07/5/2024 10:24 by troutisout Good interview.Rather than wait until the new traction is proven, those investors looking for maximum reward, must be looking at the current price and thinking about adding... |
Posted at 10/1/2024 18:13 by cumnor Yea, question is does management really have the expertise and clout to sell the brand to big investors-not penny punters. Should be an easy sell in reality-even getting the NCI in the US to show a remote interest in their antibody library is some feat one typically underappreciated by gormless UK II analysts who don't know their ars..from their elbows, and confirms the science side of things is worthwhile.Persuading IIs that a single antibody with prospects (look at GSKs deal for early phase 2 respiratory AB they paid a billion + for the right to develop-ex China-which hasn't even been approved for clinical use yet to give one an idea of the scale and potential here. I'm afraid mgmt don't seem up to it, especially if they have to resort to Proactive to sell the story for funds. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
